Our results lead us to propose that the PR isoform-specific regulation of distinct regulatory responses in the cross-talk between prolactin and FASN might be involved in the diverse phenotypic outcomes arising from the prolactin/PRLR signaling axis in luminal breast cancer. This evidence concerns the gene PGR and breast cancer.